AbESTT
AbESTT
A trial that assessed abciximab as an alternative to tPA in strokesConclusions Patients receiving abciximab were 20% more likely to have a better outcome; neurologic recovery was 29% in the treated group vs. 16% in placebo patients
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.